PCL (Polycaprolactone)
This document is technical information about materials. It does not recommend any procedure or product.
In brief
A synthetic biodegradable polyester used as a dermal biostimulatory material. It has a low melting point and a slow hydrolytic breakdown that the literature describes as longer than for lactic-acid-based polyesters.
Regulatory identity by market
COS cosmetic · MD medical device · RX drug · — not established in public sources
Identity & physical properties
| Synonyms | Polycaprolactone, Poly(epsilon-caprolactone), PCL |
|---|---|
| Formula | (C6H10O2)n |
| Family | Biostimulator — aliphatic polyester |
| Particle size | Reported in the tens of micrometres for injectable microsphere forms; varies by manufacturer |
| Morphology | Smooth spherical microspheres suspended in a carrier gel; the carrier is described in the literature as carboxymethylcellulose |
| Molecular weight | Varies by grade; the literature links chain length to the reported duration of breakdown |
Mechanism
Reviews describe a controlled foreign-body reaction to the microspheres followed by fibroblast activity and new collagen formation. A prospective human biopsy study reported increased dermal thickness after a single intradermal injection.
Evidence
| PMID | Study type | Summary |
|---|---|---|
| 36191597 | RCT | Multicentre randomised controlled trial comparing polycaprolactone gel with sodium hyaluronate for nasolabial folds |
| 32161484 | review | Review of polycaprolactone as a collagen-stimulating material in aesthetics |
| 35486036 | review | Review comparing biostimulatory effects and the level of neocollagenesis across dermal filler materials |
| 30778526 | in vivo | Prospective biopsy study of dermal thickness and histology after a single intradermal PCL injection in 13 patients |
Regulatory identity — detail
| Market | Classification | Note | Basis |
|---|---|---|---|
| KR | medical-device | Injectable forms follow the tissue-repair biomaterial route in the MFDS device classification notice. | Legal text |
| EU | medical-device | Annex XVI, Section 3 of the MDR covers substances intended for facial or other dermal filling by injection, bringing such products under the Regulation even without an intended medical purpose. | Legal text |
| US | unclassified | No FDA premarket approval record for a polycaprolactone dermal implant was found in the agency device database as of the revision date below. Absence of a record is not the same as a classification, so this is left as not established. | — |
| JP | unclassified | Not established from public sources as of the revision date below. | — |
| CN | unclassified | Not established from public sources as of the revision date below. | — |
| VN | unclassified | Not established from public sources as of the revision date below. | — |
Limitations & open questions
Published randomised comparisons are few and are mostly against hyaluronic acid rather than against other biostimulatory materials. Reported breakdown timelines derive from specific formulations rather than independent measurement, so figures quoted for one product do not describe the polymer in general. Delayed nodule and granuloma cases have been described in the literature.
All statements on this page are drawn from the cited literature. Where a market’s regulatory classification could not be established from public sources, it is marked as not established rather than inferred.
PCL shares the aliphatic polyester family with the lactic-acid-based materials but has a different repeat unit and a slower reported breakdown. When comparing published durations, check which formulation was studied: chain length and carrier differ between products, and the figures are not interchangeable.